The global “intellectual property” enforcement agenda poses profound risks for consumers in the U.S. and around the world in many ways. The risks include privacy and transparency issues and threats to access to medicines in the U.S. and the developing world.
Essential Action and other public health and consumer groups have identified several particular risks posed by the pharmaceutical monopoly enforcement agenda on access to medicines. They include:
– risks for global access to medicines and other public costs,
– how the enforcement agenda misleads policymakers and confuses public debate,
– the actual relationship between drug quality, the enforcement agenda, and counterfeit medicines,
To learn more about the the access to medicines concerns as well as to review some policy recommendations , download an Essential Action powerpoint introduction to the pharmaceutical monopoly enforcement agenda here: IPenforcementagenda.ppt